Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
← catalyst calendarNCT07311850 · readout in 398 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
3,578actual
Sites
171
Countries
Bulgaria, Canada, Czechia +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-19 | actual | When the study began enrolling |
| Primary completion | 2027-09-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity and Overweight
Interventions
- Drug: MET097 — also filed as PF-08653944
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in body weight
measured Baseline (Day 0) to Week 64
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed